Neogen vs BioLife Solutions: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Neogen Corporation (NEOG)

Q3 202624 Jul – 7 Oct 2026

▲3▼1

Neogen's growth bets meet an FDA safety blow

Q4 beat and strong FY27 guidance Neogen's fiscal fourth-quarter revenue of $225.3 million beat expectations, with core growth accelerating to 4.3% and adjusted EBITDA up 12%. It guided fiscal 2027 revenue to $880–885 million and EBITDA to $180–182 million, and repaid $20 million of debt. A stronger profit outlook lifts the stock.
The earnings beat and guidance are the core reason the stock jumped and set the period's direction.
R&D boost and Petrifilm brought in-house Neogen plans to raise fiscal 2027 R&D spending about 50% and move Petrifilm manufacturing in-house, with the first sellable output starting November 2026 and at least two new product launches a year. Doing its own manufacturing can cut costs and speed new products, supporting future profit.
This is a concrete new investment plan that shapes Neogen's growth and margins beyond the quarter.
FDA warning letters over contaminated horse product The FDA issued warning letters after fungal contamination was found in Neogen's veterinary product HYCOAT, linked to severe joint infections in nearly 100 horses and at least 20 deaths. Shares fell 5.4%. This raises regulatory, legal and reputational risk that can weigh on the stock.
It is the main negative force this period and a real counterweight to the upbeat earnings news.
Guidance raised again above consensus Neogen lifted fiscal year revenue guidance to $885–890 million, above its earlier range and the $883.2 million consensus, sending shares up 11% before the market opened. The raise signals management sees demand holding up, which supports the stock.
The fresh guidance increase is the newest positive catalyst and confirms the growth trend.

August 202624 Jul – 7 Oct 2026

▲3▼1

Neogen's growth bets meet an FDA safety blow

Q4 beat and strong FY27 guidance Neogen's fiscal fourth-quarter revenue of $225.3 million beat expectations, with core growth accelerating to 4.3% and adjusted EBITDA up 12%. It guided fiscal 2027 revenue to $880–885 million and EBITDA to $180–182 million, and repaid $20 million of debt. A stronger profit outlook lifts the stock.
The earnings beat and guidance are the core reason the stock jumped and set the period's direction.
R&D boost and Petrifilm brought in-house Neogen plans to raise fiscal 2027 R&D spending about 50% and move Petrifilm manufacturing in-house, with the first sellable output starting November 2026 and at least two new product launches a year. Doing its own manufacturing can cut costs and speed new products, supporting future profit.
This is a concrete new investment plan that shapes Neogen's growth and margins beyond the quarter.
FDA warning letters over contaminated horse product The FDA issued warning letters after fungal contamination was found in Neogen's veterinary product HYCOAT, linked to severe joint infections in nearly 100 horses and at least 20 deaths. Shares fell 5.4%. This raises regulatory, legal and reputational risk that can weigh on the stock.
It is the main negative force this period and a real counterweight to the upbeat earnings news.
Guidance raised again above consensus Neogen lifted fiscal year revenue guidance to $885–890 million, above its earlier range and the $883.2 million consensus, sending shares up 11% before the market opened. The raise signals management sees demand holding up, which supports the stock.
The fresh guidance increase is the newest positive catalyst and confirms the growth trend.

Latest24 Jul – 7 Oct 2026

▲3▼1

Neogen's growth bets meet an FDA safety blow

Q4 beat and strong FY27 guidance Neogen's fiscal fourth-quarter revenue of $225.3 million beat expectations, with core growth accelerating to 4.3% and adjusted EBITDA up 12%. It guided fiscal 2027 revenue to $880–885 million and EBITDA to $180–182 million, and repaid $20 million of debt. A stronger profit outlook lifts the stock.
The earnings beat and guidance are the core reason the stock jumped and set the period's direction.
R&D boost and Petrifilm brought in-house Neogen plans to raise fiscal 2027 R&D spending about 50% and move Petrifilm manufacturing in-house, with the first sellable output starting November 2026 and at least two new product launches a year. Doing its own manufacturing can cut costs and speed new products, supporting future profit.
This is a concrete new investment plan that shapes Neogen's growth and margins beyond the quarter.
FDA warning letters over contaminated horse product The FDA issued warning letters after fungal contamination was found in Neogen's veterinary product HYCOAT, linked to severe joint infections in nearly 100 horses and at least 20 deaths. Shares fell 5.4%. This raises regulatory, legal and reputational risk that can weigh on the stock.
It is the main negative force this period and a real counterweight to the upbeat earnings news.
Guidance raised again above consensus Neogen lifted fiscal year revenue guidance to $885–890 million, above its earlier range and the $883.2 million consensus, sending shares up 11% before the market opened. The raise signals management sees demand holding up, which supports the stock.
The fresh guidance increase is the newest positive catalyst and confirms the growth trend.

BioLife Solutions Inc (BLFS)

Q3 202622 Jul – 5 Oct 2026

▲2▼2

Repligen's $1.5B buyout locks BLFS to deal terms, not its own news

Repligen agrees to buy BioLife for $1.5 billion Repligen will pay $31 a share — $11.25 cash plus Repligen stock — a 24% premium to BioLife's recent average price. That buyout price now acts like a magnet for the stock: it trades near the deal value, and shareholders get cash plus Repligen shares when it closes.
The acquisition is the single force now setting BLFS's price.
Q2 beat shows the underlying business was healthy BioLife earned $0.04 a share versus an expected small loss, with revenue of $28.5 million, up about 21% from a year earlier and above forecasts — its fourth straight beat. Strong results support the deal price and make the buyer's case easier.
Shows the company's own performance still matters as a backstop to the deal.
Law firm probes whether the sale price is fair Investor-rights firm Halper Sadeh is investigating whether BioLife's board got shareholders a fair deal in the Repligen sale. Such reviews are common and often lead nowhere, but they can delay closing or pressure the buyer to raise its offer.
A real counterweight that could change deal terms or timing.
Removed from the S&P SmallCap 600 index BioLife is being dropped from the S&P SmallCap 600 and replaced by Freshworks, because it is being acquired. Index funds that tracked it must sell, but with the buyout nearly done, this mostly reflects the deal closing rather than new weakness.
Explains the forced selling around the deal's completion.

August 202622 Jul – 5 Oct 2026

▲2▼2

Repligen's $1.5B buyout locks BLFS to deal terms, not its own news

Repligen agrees to buy BioLife for $1.5 billion Repligen will pay $31 a share — $11.25 cash plus Repligen stock — a 24% premium to BioLife's recent average price. That buyout price now acts like a magnet for the stock: it trades near the deal value, and shareholders get cash plus Repligen shares when it closes.
The acquisition is the single force now setting BLFS's price.
Q2 beat shows the underlying business was healthy BioLife earned $0.04 a share versus an expected small loss, with revenue of $28.5 million, up about 21% from a year earlier and above forecasts — its fourth straight beat. Strong results support the deal price and make the buyer's case easier.
Shows the company's own performance still matters as a backstop to the deal.
Law firm probes whether the sale price is fair Investor-rights firm Halper Sadeh is investigating whether BioLife's board got shareholders a fair deal in the Repligen sale. Such reviews are common and often lead nowhere, but they can delay closing or pressure the buyer to raise its offer.
A real counterweight that could change deal terms or timing.
Removed from the S&P SmallCap 600 index BioLife is being dropped from the S&P SmallCap 600 and replaced by Freshworks, because it is being acquired. Index funds that tracked it must sell, but with the buyout nearly done, this mostly reflects the deal closing rather than new weakness.
Explains the forced selling around the deal's completion.

Latest22 Jul – 5 Oct 2026

▲2▼2

Repligen's $1.5B buyout locks BLFS to deal terms, not its own news

Repligen agrees to buy BioLife for $1.5 billion Repligen will pay $31 a share — $11.25 cash plus Repligen stock — a 24% premium to BioLife's recent average price. That buyout price now acts like a magnet for the stock: it trades near the deal value, and shareholders get cash plus Repligen shares when it closes.
The acquisition is the single force now setting BLFS's price.
Q2 beat shows the underlying business was healthy BioLife earned $0.04 a share versus an expected small loss, with revenue of $28.5 million, up about 21% from a year earlier and above forecasts — its fourth straight beat. Strong results support the deal price and make the buyer's case easier.
Shows the company's own performance still matters as a backstop to the deal.
Law firm probes whether the sale price is fair Investor-rights firm Halper Sadeh is investigating whether BioLife's board got shareholders a fair deal in the Repligen sale. Such reviews are common and often lead nowhere, but they can delay closing or pressure the buyer to raise its offer.
A real counterweight that could change deal terms or timing.
Removed from the S&P SmallCap 600 index BioLife is being dropped from the S&P SmallCap 600 and replaced by Freshworks, because it is being acquired. Index funds that tracked it must sell, but with the buyout nearly done, this mostly reflects the deal closing rather than new weakness.
Explains the forced selling around the deal's completion.